Yescarta is a medicine for treating adults with certain types of blood cancer: - high-grade B-cell lymphoma (HGBL); - diffuse large B-cell lymphoma (DLBCL); - primary mediastinal large B-cell lymphoma (PMBCL); - follicular lymphoma (FL). Yescarta is for use in patients whose blood cancer has returned (recurrent) or has stopped responding to previous treatment (refractory). Yescarta is a type of advanced therapy medicine called a ‘gene therapy product’. This is a type of medicine that works by delivering genes into the body. The blood cancers that Yescarta is used to treat are rare, and Yescarta was designated an ‘orphan medicine’ (a medicine used in rare diseases) for DLBCL on [16 December 2014](/en/medicines/human/orphan-designations/eu-3-14-1393), for PMBCL on [9 October 2015](/en/medicines/human/orphan-designations/eu-3-15-1553) and for FL on [11 November 2015](/en/medicines/human/orphan-designations/eu-3-15-1579). Yescarta contains the active substance axicabtagene ciloleucel (consisting of genetically modified white blood cells).
Therapeutic Indication
### Therapeutic indication Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy. Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01XX70
ATC Item
xl 01 xx 70
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Yescarta
Medicine Name
Yescarta
Aliases
N/A
